- Home
- ML vs EOLS Comparison
ML vs EOLS Comparison
Compare ML & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ML
- EOLS
- Stock Information
- Founded
- ML 2013
- EOLS 2012
- Country
- ML United States
- EOLS United States
- Employees
- ML N/A
- EOLS N/A
- Industry
- ML Retail: Computer Software & Peripheral Equipment
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- ML Technology
- EOLS Health Care
- Exchange
- ML Nasdaq
- EOLS Nasdaq
- Market Cap
- ML 434.8M
- EOLS 1.1B
- IPO Year
- ML N/A
- EOLS 2018
- Fundamental
- Price
- ML $48.30
- EOLS $16.63
- Analyst Decision
- ML Strong Buy
- EOLS Strong Buy
- Analyst Count
- ML 7
- EOLS 6
- Target Price
- ML $92.83
- EOLS $22.60
- AVG Volume (30 Days)
- ML 179.8K
- EOLS 644.7K
- Earning Date
- ML 11-07-2024
- EOLS 11-05-2024
- Dividend Yield
- ML N/A
- EOLS N/A
- EPS Growth
- ML N/A
- EOLS N/A
- EPS
- ML 0.16
- EOLS N/A
- Revenue
- ML $475,073,000.00
- EOLS $237,260,000.00
- Revenue This Year
- ML $28.87
- EOLS $34.62
- Revenue Next Year
- ML $19.72
- EOLS $33.33
- P/E Ratio
- ML $293.01
- EOLS N/A
- Revenue Growth
- ML 23.75
- EOLS 40.71
- 52 Week Low
- ML $17.40
- EOLS $7.44
- 52 Week High
- ML $106.82
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- ML 64.04
- EOLS 52.28
- Support Level
- ML $39.55
- EOLS $16.38
- Resistance Level
- ML $49.53
- EOLS $17.57
- Average True Range (ATR)
- ML 2.51
- EOLS 0.77
- MACD
- ML 1.28
- EOLS -0.04
- Stochastic Oscillator
- ML 90.45
- EOLS 42.51
About ML MoneyLion Inc.
MoneyLion Inc is a mobile banking and financial membership platform that empowers people to take control of their finances. It is a full-service digital platform to deliver mobile banking, lending, and investment solutions. The company offers a personalized, all-in-one, digital financial platform that provides convenient, low-cost access to banking, borrowing, and investing solutions tailored for its customers, rooted in data, and delivered through its proprietary technology platform.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.